目的 觀察心舒寶片聯(lián)合尼可地爾片治療冠心病心絞痛的臨床療效。方法 選擇2021年6月-2022年6月于鄭州大學(xué)第一附屬醫(yī)院診治的136例冠心病心絞痛患者為研究對(duì)象,按照雙色球法將患者分為對(duì)照組和治療組,各為68例。對(duì)照組口服尼可地爾片,5 mg/次,3次/d。治療組患者在對(duì)照組基礎(chǔ)上飯后口服心舒寶片,1~2片/次,2次/d。兩組患者均連續(xù)治療3個(gè)月。比較兩組臨床療效、臨床癥狀、心功能指標(biāo)、血液流變學(xué)指標(biāo)和氧化應(yīng)激指標(biāo)。結(jié)果 治療后,治療組的總有效率(94.12%)明顯高于對(duì)照組(76.47%)(P<0.05)。治療后,兩組心絞痛發(fā)作次數(shù)減少、每次持續(xù)時(shí)間縮短、日均硝酸甘油用量減少,心排血量(CO)、左心室射血分?jǐn)?shù)(LVEF)、心排血指數(shù)(CI)均顯著升高,血漿黏度、全血高切黏度、全血低切黏度下降,血清超氧化物歧化酶(SOD)水平升高,血清丙二醛(MDA)水平下降(P<0.05),且治療組臨床癥狀、心功能指標(biāo)、血液流變學(xué)指標(biāo)、血清氧化應(yīng)激指標(biāo)的改善程度較對(duì)照組更大(P<0.05)。結(jié)論 心舒寶片聯(lián)合尼可地爾片治療冠心病心絞痛,能夠明顯改善心絞痛癥狀、血液流變學(xué),減輕氧化應(yīng)激癥狀。

Objective To observe the clinical effect of Xinshubao Tablets combined with Nicorandil Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (136 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Zhengzhou University from June 2021 to June 2022 were divided into control and treatment groups according to the bicolor sphere method, and each group had 68 cases. Patients in the control group were po administered with Nicorandil Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Xinshubao Tablets after meals on the basis of the control group, 1-2 tablets/time, twice daily. Patients in two groups were treated for 3 months. The clinical efficacies, the clinical symptoms, cardiac function indicators, hemorheological indicators, and oxidative stress indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group (94.12%) was significantly higher than76.47% of the control group (P < 0.05). After treatment, the frequency of angina pectoris attacks, the duration of angina pectoris attacks, and the daily dosage of nitroglycerin were decreased, CO, LVEF, and CI were significantly increased, the plasma viscosity, whole blood high tangential viscosity, and whole blood low tangential viscosity were decreased, the serum level of SOD increased, but the serum level of MDA decreased in two groups (P < 0.05), and the improvement of clinical indexes in the treatment group was better than those in the control group (P < 0.05). Conclusion Xinshubao Tablets combined with Nicorandil Tablets in the treatment of angina pectoris of coronary heart disease has a good improvement effect in treatment of angina pectoris, can significantly improve angina symptoms, hemorheology, and alleviate oxidative stress symptoms.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20210264）